Marvel Biosciences Announces Stock Option Grants

Rhea-AI Summary

Marvel Biosciences Corp. (TSXV: MRVL) has announced the grant of 1,475,000 incentive stock options to certain directors and officers. The options, approved on July 23, 2024, have an exercise price of $0.125 per share, matching the closing price on July 22, 2024. These options are exercisable until July 23, 2029, and will vest in three tranches: 1/3 immediately, 1/3 on the first anniversary, and 1/3 on the second anniversary of the grant. The stock options are subject to the company's stock option plan and TSX Venture Exchange requirements.

Positive

• Incentive alignment between management and shareholders through stock option grants
• Five-year exercise period for the options, providing long-term incentives

Negative

• Potential dilution of existing shareholders' ownership if options are exercised

Calgary, Alberta--(Newsfile Corp. - July 25, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announce that, effective July 23, 2024, its board of directors approved the grant of incentive stock options (the "Options") to certain directors and officers to acquire an aggregate of 1,475,000 common shares in the capital of the Company at an exercise price of $0.125, being the closing price of the Company's common shares on the TSX Venture Exchange ("TSX-V") on July 22, 2024. All Options were granted pursuant to the Company's stock option plan (the "Plan") and are subject to the terms of the Plan, the applicable grant agreements and the requirements of the TSX-V.

The Options are exercisable any time until 5:00 p.m. (Mountain Time) on July 23, 2029. The Options will vest: (i) 1/3 immediately; (ii) 1/3 on the first anniversary of the grant; and (iii) 1/3 on the second anniversary of the grant.

Contact Information

Marvel Biosciences Corp.
Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer
Tel: 403 770 2469

Email: info@marvelbiosciences.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

All information contained in this news release with respect to the Company and its subsidiary, (collectively, the "Parties") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and officers have relied on each other for any information concerning such Party.

This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/217713

FAQ

How many stock options did Marvel Biosciences (TSXV: MRVL) grant on July 23, 2024?

Marvel Biosciences (TSXV: MRVL) granted 1,475,000 incentive stock options to certain directors and officers on July 23, 2024.

What is the exercise price of the stock options granted by Marvel Biosciences (TSXV: MRVL) in July 2024?

The exercise price of the stock options granted by Marvel Biosciences (TSXV: MRVL) is $0.125 per share, which was the closing price of the company's shares on the TSX Venture Exchange on July 22, 2024.

When do the stock options granted by Marvel Biosciences (TSXV: MRVL) in July 2024 expire?

The stock options granted by Marvel Biosciences (TSXV: MRVL) in July 2024 expire on July 23, 2029, giving option holders a five-year exercise period.

What is the vesting schedule for the stock options granted by Marvel Biosciences (TSXV: MRVL) in July 2024?

The vesting schedule for the stock options is: 1/3 immediately, 1/3 on the first anniversary of the grant, and 1/3 on the second anniversary of the grant.